Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$137.77 USD

137.77
2,784,193

+1.25 (0.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $138.00 +0.23 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Zimmer Biomet Strong on Positive Data From PROGRESS II Study

by Zacks Equity Research

Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.

    Zacks Equity Research

    Here's Why You Should Invest in Masimo (MASI) Right Now

    by Zacks Equity Research

    Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

      Zacks Equity Research

      Haemonetics Banks on Hospital Business, Competition Rife

      by Zacks Equity Research

      For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.

        Zacks Equity Research

        Abbott Rides High on FDA Approvals & Buyouts Amid Headwinds

        by Zacks Equity Research

        Abbott (ABT) appears to gain traction from the current integration and synergy achievement of St. Jude. Meanwhile, the company's recent closure of Alere takeover is another positive.

          Zacks Equity Research

          LabCorp (LH) at a 52-Week High: What's Driving the Stock?

          by Zacks Equity Research

          LabCorp (LH) banks on Chiltern International Group's buyout. An upbeat guidance boosts investors' confidence.

            Zacks Equity Research

            AmerisourceBergen Banks on Strategic Deals, Competition Rife

            by Zacks Equity Research

            AmerisourceBergen (ABC) enters a strategic agreement with Walgreen Boots Alliance.

              Zacks Equity Research

              Abbott (ABT) at a 52-Week High: What's Driving the Stock?

              by Zacks Equity Research

              Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.

                Zacks Equity Research

                PerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B

                by Zacks Equity Research

                PerkinElmer (PKI) focuses on inorganic growth through acquisition.

                  Zacks Equity Research

                  DexCom (DXCM) Banks on Collaborations, Competition Rife

                  by Zacks Equity Research

                  DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.

                    Zacks Equity Research

                    NuVasive (NUVA) Global Prospects Solid, Pricing Woes Remain

                    by Zacks Equity Research

                    NuVasive (NUVA) witnesses solid top-line contributions from the international business.

                      Zacks Equity Research

                      Innovation, Partnership Aid Genomic Health, Cost Woe Remains

                      by Zacks Equity Research

                      Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.

                        Zacks Equity Research

                        TransEnterix & GBIL Ink Deal to Commercialize SurgiBot System

                        by Zacks Equity Research

                        TransEnterix (TRXC) to retain distribution rights of SurgiBot System outside China.

                          Sweta Killa headshot

                          5 Hot Stocks Driving the Nasdaq ETF Rally

                          by Sweta Killa

                          Inside the top performing stocks of the Nasdaq ETF.

                            Zacks Equity Research

                            Henry Schein Buys eVetPractice, Boosts Technology & VAS Arm

                            by Zacks Equity Research

                            Henry Schein (HSIC) adopts initiatives to strengthen hold in the high-potential healthcare IT market.

                              Zacks Equity Research

                              Amedisys (AMED) Banks on Personal Care Amid Margin Woes

                              by Zacks Equity Research

                              Amedisys' (AMED) efforts have helped turn around the Personal Care business.

                                Zacks Equity Research

                                Express Scripts Buys eviCore for $3.6B, Forays Into MBM

                                by Zacks Equity Research

                                The eviCore buyout boosts Express Scripts' (ESRX) ability to drive value in the use of Specialty medications.

                                  Zacks Equity Research

                                  Teleflex (TFX), HealthTrust Rebond on Respiratory Products

                                  by Zacks Equity Research

                                  Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.

                                    Zacks Equity Research

                                    Walgreens Closes PharMerica Buyout as KKR's Minority Partner

                                    by Zacks Equity Research

                                    Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.

                                      Zacks Equity Research

                                      Genomic Health at a 52-Week High: What's Driving the Stock?

                                      by Zacks Equity Research

                                      Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

                                        Zacks Equity Research

                                        Myriad Genetics Presents Favorable EMBRACA Trial Results

                                        by Zacks Equity Research

                                        Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.

                                          Zacks Equity Research

                                          Wright Medical (WMGI) Acquires IMASCAP SAS for $88.8 Million

                                          by Zacks Equity Research

                                          Wright Medical's (WMGI) acquisition of IMASCAP SAS will strengthen Extremities business.

                                            Zacks Equity Research

                                            Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                            by Zacks Equity Research

                                            Illumina (ILMN) banks on product launches and international market prospects.

                                              Zacks Equity Research

                                              Myriad Genetics Rides on Solid Molecular Diagnostics Suite

                                              by Zacks Equity Research

                                              Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.

                                                Zacks Equity Research

                                                CVS Health Banks on Solid Pharmacy Services, Competition Rife

                                                by Zacks Equity Research

                                                CVS Health's (CVS) strong 2018 PBM selling season buoys optimism.

                                                  Zacks Equity Research

                                                  NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM

                                                  by Zacks Equity Research

                                                  NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.